Total Voting Rights


3 October 2016 15:00

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct
Authority's Disclosure and Transparency Rule 5.6.1. On 30 September 2016 the
issued share capital of AstraZeneca PLC with voting rights is 1,265,021,933
ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total
number of voting rights in AstraZeneca PLC is 1,265,021,933.

The above figure for the total number of voting rights may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to their
interest in, AstraZeneca PLC under the UK Financial Conduct Authority's
Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media   Enquiries
Neil   Burrows       UK/Global                              +44 203 749 5637
Vanessa   Rhodes     UK/Global                              +44 203 749 5736
Karen   Birmingham   UK/Global                              +44 203 749 5634
Rob   Skelding       UK/Global                              +44 203 749 5821
Jacob   Lund         Sweden                                 +46 8 553 260 20
Michele   Meixell    US                                     +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen                                         +44 203 749 5712
Craig   Marks        Finance,   Fixed Income, M&A           +44 7881 615 764
Nick   Stone         Respiratory   & Autoimmunity           +44 203 749 5716
Henry   Wheeler      Oncology                               +44 203 749 5797
Christer   Gruvris   Infection   & Neuroscience             +44 203 749 5711
US
Lindsey   Trickett   Cardiovascular   & Metabolic Diseases  +1 240 543 7970
Mitchell   Chan      Oncology                               +1 240 477 3771
Toll-free                                                   +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

Attachments

10033143.pdf